Novel Likely Pathogenic Variant in the A3 Domain of von Willebrand Factor Leading to a Collagen-Binding Defect

Salome Fels¹ Doris Boeckelmann¹ Hannah Glonnegger¹ Martin Büchsel² Barbara Zieger¹

Address for correspondence Barbara Zieger, MD, Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Faculty of Medicine, Medical Center – University of Freiburg, Mathildenstrasse 1, 79106 Freiburg, Germany (e-mail: barbara.zieger@uniklinik-freiburq.de).

Hamostaseologie 2023;43:122-125.

Abstract

Keywords

- von Willebrand factor
- von Willebrand disease
- type 2M
- collagen-binding domain

Von Willebrand disease (VWD) is the most prevalent congenital bleeding disorder. Diagnosis and classification of VWD is complex due to its heterogeneity regarding clinical manifestations and molecular genetic analysis. Genetic investigations became an inherent part of diagnosis and help distinguish different types/subtypes of VWD. Although many variants have been listed being causative for VWD, the genetic etiology remains undefined in a lot of patients. We report about two siblings with severely reduced values for von Willebrand factor collagen-binding activity (VWF:CB). Genetic analysis using panel sequencing identified a heterozygous non-synonymous single nucleotide variant in exon 30. At the protein level, the alteration (p.Ser1731Leu) is located in the A3 collagen-binding domain. The amino acid position is already known to be important for collagen binding because p.Ser1731Thr has been reported to affect the VWF:CB.

Introduction

Von Willebrand disease (VWD) is caused by genetic variants in the von Willebrand factor (*VWF*) gene resulting in quantitative (types 1 and 3) and qualitative (type 2) deficiencies of VWF. Main characteristics are prolonged bleeding time, tendency for hematomas, and mucocutaneous bleedings such as epistaxis and menorrhagia. Type 2M VWD is due to autosomal dominant variants either in A1 or A3 domain of VWF. Variants in A1 domain lead to defective binding of VWF to platelet Gplb without loss of high-molecular-weight multimers. Defects in A3 domain are characterized by reduced binding activity of VWF to subendothelial collagen type I and type III. Patients with a collagen-binding defect show low values for VWF:CB (VWF:collagen-binding activity) and VWF:CB/VWF:antigen (Ag) ratio, whereas other VWF parameters and multimeric patterns are normal. Genetic analysis

using next-generation sequencing (NGS) for the large VWF has replaced former sequential Sanger sequencing.

Case Report

We investigated two siblings (one girl and one boy) with a bleeding diathesis. The boy (13 years old) suffered from several bleedings after tonsillectomy and recurrent epistaxis. The older sister (16 years old) presented with menorrhagia, intermittent gum bleeding, and easy bruising. Both siblings showed severely decreased values for VWF:CB (≤0.11 U/mL) and VWF:CB/VWF:Ag ratio (0.06 and 0.16, respectively). VWF:CB measured in the patients corresponds to collagen type I (Takeda, Austria GmbH). VWF activity (VWF:GPlbM) was analyzed using VWF:Ac INNOVANCE VWFAc (Siemens Healthcare Diagnostics). Values for VWF:Ag, VWF:Ac, factor VIII activity (►Table 1), and multimer analysis (►Fig. 1) were

received July 14, 2021 accepted after revision November 19, 2021 © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany DOI https://doi.org/ 10.1055/a-1701-2181. ISSN 0720-9355.

¹ Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Faculty of Medicine, Medical Center – University of Freiburg, Germany

²Institute of Clinical Chemistry and Laboratory Medicine, Faculty of Medicine, Medical Center – University of Freiburg, Germany

Table 1 VWF diagnostic for the two siblings

Patient	VWF:Ag [U/mL] normal: 0.6–1.5	VWF:CB [U/mL] normal: 0.6–1.5	VWF:CB/VWF:Ag ratio normal: 0.8–1.5	VWF:Ac [%] normal: 46–179	Multimer analysis	FVIII activity [%] normal: 60–150
Brother	0.70	0.09	0.13	60	Normal	100
	0.83	0.05	0.06	68	n.d.	n.d.
Sister	0.69	0.11	0.16	57	Normal	90
	0.74	0.05	0.07	67	n.d.	n.d.

Abbreviations: n.d., not done; VWF, von Willebrand factor.




Fig. 1 SDS agarose gel electrophoresis of von Willebrand factor multimers, visualized by enzyme immunostaining after capillary transfer onto PVDF (polyvinylidene difluoride) membranes. Multimeric analysis was performed by SDS-agarose gel electrophoresis in 1.0% (**A**) and in 2.2% (**B**) SDS-agarose gels (demonstrated for the boy).

normal. For genetic analysis, we performed NGS using enriched gene panel diagnostics (Nextera Rapid Custom Enrichment Kit followed by sequencing on a MiSeq; both Illumina, San Diego, California, United States). The coverage for the enriched sequence of the VWF reached 99% for 20× and 97% for $100 \times$. In exon 30 (NM_000552.3), we identified a heterozygous nsSNV (c.5192C > T) (\sim Fig. 2). The nsSNV is listed in dbSNP (rs764077750) and gnomAD (genome aggregation database) with rare minor allele frequency (ALL: 0.0012%). The variant is leading to an amino acid substitution from serine to leucine at position 1731 (p.Ser1731Leu) within the A3 domain of VWF. The A3 domain is considered to be the major binding site for collagen types I and III. In silico pathogenicity prediction is concordant pathogenic (SIFT, MutationTaster, PolyPhen2, CADD; **Table 2**). The variant is absent in the locus-specific database EAHAD and the public version of HGMD (Human Gene Mutation Database) (accessed July 10, 2021). However, the amino acid position p.1731 has been described with threonine instead of wild-type serine (p. Ser1731Thr) to be present in two patients with reduced




Fig. 2 Molecular genetic analysis; NM_000552.3(VWF):c.5192[C > T];[=] (p.S1731L).

Table 2 In silico pathogenicity prediction for VWF variant p. Ser1731Leu

Program	Output		
SIFT	Deleterious (score: 0.01, median: 3.34)		
MutationTaster	Disease causing (prob: 1)		
PolyPhen2 HumDiv	Probably damaging (score: 0.983)		
CADD score	26.5		

Abbreviation: VWF, von Willebrand factor.

binding of VWF to collagen. Expression of the VWF mutant p.Ser1731Thr in COS7 cells confirmed the functional defect.³ Based on these findings, we classified p.Ser1731Leu as *novel* likely pathogenic variant within the A3 domain of VWF causing VWD type 2M CBD.

Conflict of Interest

B.Z. received research funding from Biotest AG, Takeda, and CSL Behring and honoraria for lectures from Bayer and CSL Behring. M.B. received travel support from Takeda, CSL Behring, SOBI, and Bayer.

Acknowledgment

The authors thank Biotest AG for funding this study.

References

- 1 Lankhof H, van Hoeij M, Schiphorst ME, et al. A3 domain is essential for interaction of von Willebrand factor with collagen type III. Thromb Haemost 1996;75(06):950–958
- 2 Riddell AF, Gomez K, Millar CM, et al. Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor. Blood 2009;114 (16):3489–3496
- 3 Ribba AS, Loisel I, Lavergne JM, et al. Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Thromb Haemost 2001;86(03):848–854